Stock Taper 
Pharming Group N.V. is a biopharmaceutical company developing protein replacement therapies and precision medicines for rare diseases, with products like Ruconest for hereditary angioedema and collaborations with Novartis and Orchard Therapeutics.
Joenja® is the first FDA-approved oral PI3Kδ inhibitor for APDS in patients 12+, marking a significant milestone for Pharming Group with a successful U.S. launch and strong initial patient uptake.
Pharming Group announced preliminary full-year 2025 revenues of approximately $376 million, surpassing its upwardly revised guidance and representing about 27% growth over 2024. This significant financial milestone was driven by the strong and growing demand for its commercial products, RUCONEST® and Joenja®, putting the company in a significant spotlight for investors.
Pharming Group announced a significant organizational restructuring in late 2025 aimed at optimizing capital allocation and enhancing operational efficiency. The plan involves a strategic redesign of the company's structure and a reduction in workforce to lower administrative expenses and focus resources on growth drivers.
RUCONEST is Pharming Group's main revenue source today. This asset has already shown a sequential sales rebound that makes me more optimistic. However, RUCONEST still has oral competition that could make stabilizing that revenue bleed more challenging. Still, my bull case assumes RUCONEST's issues are manageable. If so, that could buy time for Joenja to grow and improve the business mix.
Overall rating: B-
| PEER | PRICE | |
|---|---|---|
 BMRN | $54.85 | COMPARE |
 IONS | $43.68 | COMPARE |
 TNGX | $21.45 | COMPARE |
 PHVS | $31.61 | COMPARE |
 BCRX | $8.34 | COMPARE |
 FTRE | $21.52 | COMPARE |
 PVLA | $128.77 | COMPARE |
 NTLA | $12.10 | COMPARE |
